
Annual report 2025
added 02-13-2026
Outset Medical Retained Earnings 2011-2026 | OM
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Outset Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.17 B | -1.09 B | -962 M | -789 M | -626 M | - | -373 M | -288 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -288 M | -1.17 B | -757 M |
Quarterly Retained Earnings Outset Medical
| 2025-Q3 | 2024-Q4 | 2024-Q3 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.15 B | -1.09 B | - | - | - | - | -663 M | -626 M | -585 M | -554 M | -524 M | -494 M | -494 M | -494 M | -494 M | -373 M | -373 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -373 M | -1.15 B | -609 M |
Retained Earnings of other stocks in the Medical devices industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aethlon Medical
AEMD
|
-168 M | $ 2.11 | 8.21 % | $ 3.29 M | ||
|
AdaptHealth Corp.
AHCO
|
-633 M | $ 10.42 | -1.65 % | $ 1.41 B | ||
|
Allied Healthcare Products
AHPI
|
-15.7 M | - | 3.58 % | $ 2.21 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
-533 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
-600 M | - | -26.83 % | $ 2.62 M | ||
|
Alphatec Holdings
ATEC
|
-1.42 B | $ 12.6 | 2.61 % | $ 1.89 B | ||
|
Butterfly Network
BFLY
|
-802 M | $ 3.91 | 2.62 % | $ 828 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-185 M | - | -5.86 % | $ 30.6 M | ||
|
Cognyte Software Ltd.
CGNT
|
-157 M | $ 8.38 | -0.24 % | $ 602 M | ||
|
Aziyo Biologics
AZYO
|
-176 M | - | 1.37 % | $ 20.5 M | ||
|
Avinger
AVGR
|
-421 M | - | -20.74 % | $ 369 K | ||
|
BIOLASE
BIOL
|
-317 M | - | -13.19 % | $ 166 K | ||
|
Boston Scientific Corporation
BSX
|
5.57 B | $ 69.79 | 0.95 % | $ 103 B | ||
|
Conformis
CFMS
|
-581 M | - | - | $ 16.4 M | ||
|
EDAP TMS S.A.
EDAP
|
-82.6 M | $ 3.96 | 1.02 % | $ 148 M | ||
|
CONMED Corporation
CNMD
|
589 M | $ 37.41 | 0.35 % | $ 1.16 B | ||
|
Apollo Endosurgery
APEN
|
-337 M | - | - | $ 475 M | ||
|
Cytosorbents Corporation
CTSO
|
-304 M | $ 0.65 | -8.13 % | $ 35.4 M | ||
|
Cutera
CUTR
|
-303 M | - | -10.19 % | $ 1.99 M | ||
|
CryoLife, Inc.
CRY
|
20 M | - | -4.14 % | $ 702 M | ||
|
Dynatronics Corporation
DYNT
|
-40.5 M | - | 14.99 % | $ 929 K | ||
|
ClearPoint Neuro
CLPT
|
-191 M | $ 11.03 | 2.22 % | $ 298 M | ||
|
Establishment Labs Holdings
ESTA
|
-496 M | $ 63.48 | 0.21 % | $ 1.88 B | ||
|
Axonics Modulation Technologies
AXNX
|
-374 M | - | - | $ 3.31 B | ||
|
Soliton, Inc.
SOLY
|
-70.6 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
-56.2 M | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-119 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
-39.3 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-395 M | - | - | $ 111 M | ||
|
FONAR Corporation
FONR
|
-33.6 M | $ 18.42 | 0.22 % | $ 121 M | ||
|
InMode Ltd.
INMD
|
969 M | $ 13.43 | -0.81 % | $ 868 M | ||
|
GBS
GBS
|
-62.5 M | - | -0.57 % | $ 7.12 M | ||
|
Intersect ENT, Inc.
XENT
|
-303 M | - | - | $ 955 M | ||
|
Abbott Laboratories
ABT
|
49.8 B | $ 109.95 | 1.8 % | $ 191 B | ||
|
Delcath Systems
DCTH
|
-529 M | $ 9.81 | 3.81 % | $ 351 M | ||
|
Bio-Rad Laboratories
BIO
|
7.42 B | $ 261.24 | -0.59 % | $ 7.37 B | ||
|
Helius Medical Technologies
HSDT
|
-160 M | $ 2.19 | 3.79 % | $ 1.33 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
940 M | $ 9.01 | -2.49 % | $ 694 M | ||
|
AxoGen
AXGN
|
-307 M | $ 32.84 | 1.55 % | $ 1.51 B | ||
|
Align Technology
ALGN
|
2.48 B | $ 169.45 | 3.18 % | $ 12.7 B | ||
|
Bruker Corporation
BRKR
|
2.41 B | $ 32.76 | -2.93 % | $ 4.88 K | ||
|
IRIDEX Corporation
IRIX
|
-79 M | $ 1.33 | 2.31 % | $ 21.5 M | ||
|
BioSig Technologies
BSGM
|
-255 M | - | 37.08 % | $ 85.7 M | ||
|
Apyx Medical Corporation
APYX
|
-89.1 M | $ 3.67 | 1.1 % | $ 151 M | ||
|
OrthoPediatrics Corp.
KIDS
|
-275 M | $ 17.11 | -1.16 % | $ 401 M | ||
|
Integer Holdings Corporation
ITGR
|
994 M | $ 84.12 | 1.34 % | $ 2.92 B | ||
|
Invacare Corporation
IVC
|
-78.4 M | - | - | $ 24.7 M | ||
|
Second Sight Medical Products
EYES
|
-122 M | - | -0.97 % | $ 54.4 M |